Most Read Articles
01 Dec 2019
Macrolide antibiotics are derived from the Streptomycesspecies. These contain either 14-membered (erythromycin [ERM],clarithromycin [CAM], roxithromycin [RXM]), 15-membered(azithromycin [AZM]) or 16-membered (spiramycin, josamycin,midecamycin) macrocyclic lactone rings. They inhibit proteinsynthesis by reversibly binding to the 23S ribosomal RNA (rRNA)in the 50s subunit of the bacterial ribosome. Traditionally,macrolides are used as first-line agents in respiratory, skin,soft tissue, and urogenital infections, and they are also activeagainst gram-positive cocci and atypical pathogens.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Jairia Dela Cruz, 5 days ago
Nonsmall cell lung cancer (NSCLC) patients harbouring sensitive EGFR mutations may fare well with the third-generation tyrosine kinase inhibitor osimertinib as an upfront therapy, with the results of a network meta-analysis showing that the drug tops other currently available options in terms of progression-free survival and tolerability.
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.

Vedolizumab useful, safe for long-term treatment of inflammatory bowel disease

Jairia Dela Cruz
24 Jan 2020

Most patients with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD) on vedolizumab (VDZ) persist with their treatment for up to 5 years, according to a posthoc analysis of the phase III GEMINI long-term safety (LTS) study presented at the Advances in Inflammatory Bowel Diseases (AIBD) 2019 Annual Meeting.

“These findings … support the longer-term effectiveness and safety of VDZ in patients with moderately to severely active UC and CD,” according to the researchers.

The analysis included 190 patients with UC (mean disease duration, 8.7 years) and 231 with CD (mean disease duration, 10.6 years) from GEMINI LTS who had received VDZ every 4 weeks. These patients had no previous exposure to the drug (de novo cohort). Majority of the population—61 percent in the UC group and 74 percent in the CD groups—had prior antitumour necrosis factor (anti-TNF) inhibitor failure.

Over a 5-year follow-up, 276 patients (66 percent) discontinued VDZ. Commonly endorsed reasons were lack of efficacy (24 percent and 33 percent, respectively) and adverse events (AEs; 16 percent of patients in the group; 17 percent in the CD group). [AIBD 2019, abstract P055]

On Kaplan-Meier survival analysis, treatment persistence rates at month 54 were 53 percent in the UC group and 41 percent in the CD group. The rates were much higher among patients who did vs did not show response at week 12 (UC: 60 percent vs 26 percent; p<0.0001; CD: 42 percent vs 35 percent; p=0.001), as well as among patients without vs with prior anti-TNF failure (UC: 63 percent vs 47 percent; p=0.046; CD: 47 percent vs 42 percent; p=0.016).

Among patients with baseline anti-TNF failure, those with secondary vs primary nonresponse in the UC group had markedly higher 54-month VDZ treatment persistence rates (65 percent vs 15 percent; p<0.0001). This difference was not seen in the CD group (44 percent vs 40 percent; p=0.573).

Concomitant therapy had no impact on treatment persistence.

A gut-selective, humanized monoclonal antibody, VDZ is approved for the treatment of moderately to severely active IBD. It is available in single-use vials containing 300 mg of lyophilized VDZ.

“Although VDZ efficacy and safety are well established, there are limited publications on longer-term (>3 years) treatment persistence,” according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2019
Macrolide antibiotics are derived from the Streptomycesspecies. These contain either 14-membered (erythromycin [ERM],clarithromycin [CAM], roxithromycin [RXM]), 15-membered(azithromycin [AZM]) or 16-membered (spiramycin, josamycin,midecamycin) macrocyclic lactone rings. They inhibit proteinsynthesis by reversibly binding to the 23S ribosomal RNA (rRNA)in the 50s subunit of the bacterial ribosome. Traditionally,macrolides are used as first-line agents in respiratory, skin,soft tissue, and urogenital infections, and they are also activeagainst gram-positive cocci and atypical pathogens.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Jairia Dela Cruz, 5 days ago
Nonsmall cell lung cancer (NSCLC) patients harbouring sensitive EGFR mutations may fare well with the third-generation tyrosine kinase inhibitor osimertinib as an upfront therapy, with the results of a network meta-analysis showing that the drug tops other currently available options in terms of progression-free survival and tolerability.
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.